Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect study of AG-120 in healthy subjects
NCT02579707Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ivosidenib in acute myeloid leukemia (AML) and cholangiocarcinoma (CCA) (3 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 504 hours, Incidence of Adverse Events at 22 days and 4 more. Started Oct 2015; status: completed.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02579707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579707.